Evidence map›Paper›PMID 38620916›Full record

ArticleThrombosis update2022

Thromboembolic complications during and after hospitalization for COVID-19: Incidence, risk factors and thromboprophylaxis.

Birgitte Tholin, Hilde Fiskvik, Anders Tveita, Galina Tsykonova, Helene Opperud, Kari Busterud, Clarisse Mpinganzima, Lamya Garabet, Jamal Ahmed, Knut Stavem and 1 more

Open access · goldAbstract read
In one paragraph

Article in Thrombosis update, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. A systematic review on post-discharge venous thromboembolism prophylaxis in patients with COVID-19.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 1 country.

Birgitte TholinClinic of Internal Medicine, Østfold Hospital, Norway.
Hilde FiskvikDepartment of Haematology, Oslo University Hospital Ullevål, Oslo, Norway.
Anders TveitaDepartment of Internal Medicine, Bærum Hospital, Norway.
Galina TsykonovaClinic of Internal Medicine, Østfold Hospital, Norway.
Helene OpperudClinic of Internal Medicine, Østfold Hospital, Norway.
Kari BusterudDepartment of Haematology, Akershus University Hospital, Lørenskog, Norway.
Clarisse MpinganzimaDepartment of Haematology, Stavanger University Hospital, Norway.
Lamya GarabetDepartment of Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus University Hospital, Norway.
Jamal AhmedClinic of Internal Medicine, Østfold Hospital, Norway.
Knut StavemInstitute of Clinical Medicine, University of Oslo, Norway.
Waleed GhanimaClinic of Internal Medicine, Østfold Hospital, Norway.
University of Oslo · NOAkershus University Hospital · NOOslo University Hospital · NOØstfold Hospital Trust · NOBærum Sykehus · NOStavanger University Hospital · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: The incidence of thromboembolism during COVID-19 and the use of thromboprophylaxis vary greatly between studies. Only a few studies have investigated the rate of thromboembolism post-discharge. This study determined the 90-day incidence of venous and arterial thromboembolic complications, risk factors for venous thromboembolic events and characterized the use of thromboprophylaxis during and after hospitalization. Materials and methods: We retrospectively reviewed medical records for adult patients hospitalized for >24 h for COVID-19 before May 15, 2020, in ten Norwegian hospitals. We extracted data on demographics, thromboembolic complications, thromboembolic risk factors, and the use of thromboprophylaxis. Cox proportional hazards regression was used to determine risk factors for VTE. Results: 550 patients were included. The 90-day incidence of arterial and venous thromboembolism in hospitalized patients was 6.9% (95% CI: 5.1-9.3) overall and 13.8% in the ICU. Male sex (hazard ratio (HR) 7.44, 95% CI 1.73-32.02, Conclusions: The 90-day incidence of thromboembolism in COVID-19 patients was 7%, but <1% after discharge. Risk factors were male sex and previous VTE. Most patients received thromboprophylaxis during hospitalization, but only <10% after discharge.

Indexed as

COVID-19Risk factorsThromboembolismThromboprophylaxis

Identifiers

PMID38620916
PMCPMC8720677
OpenAlexW4205943656

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.